Bionano Genomics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $8M | ↓-2.6% | — | — | — |
| 2025-09-30 | $7M | ↑+21.3% | $-9M | ↑+80.8% | -115.9% |
| 2025-06-30 | $7M | ↓-13.4% | $-7M | ↑+57.7% | -115.8% |
| 2025-03-31 | $6M | ↓-26.4% | $-3M | ↑+90.1% | -131.1% |
| 2024-12-31 | $8M | ↓-23.9% | — | — | — |
| 2024-09-30 | $6M | ↓-34.8% | $-44M | ↑+60.7% | -722.9% |
| 2024-06-30 | $8M | ↓-10.3% | $-16M | ↑+58.3% | -219.0% |
| 2024-03-31 | $9M | ↑+18.3% | $-31M | ↑+15.4% | -354.9% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$8M
↓-2.6% -$212K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
BNGO Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyBNGO Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics